PureTech Health Operating Income Over Time
| PRTC Stock | USD 18.08 0.43 2.44% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out PureTech Health Performance and PureTech Health Correlation. Will Biotechnology sector continue expanding? Could PureTech diversify its offerings? Factors like these will boost the valuation of PureTech Health. Anticipated expansion of PureTech directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every PureTech Health data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.615 | Earnings Share 1.7 | Revenue Per Share | Quarterly Revenue Growth 5.427 | Return On Assets |
The market value of PureTech Health PLC is measured differently than its book value, which is the value of PureTech that is recorded on the company's balance sheet. Investors also form their own opinion of PureTech Health's value that differs from its market value or its book value, called intrinsic value, which is PureTech Health's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because PureTech Health's market value can be influenced by many factors that don't directly affect PureTech Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between PureTech Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PureTech Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, PureTech Health's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare PureTech Health PLC and related stocks such as Autolus Therapeutics, Neurogene, and Solid Biosciences LLC Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUTL | (57.5 M) | (57.5 M) | (57.5 M) | (57.5 M) | (57.5 M) | (8.1 M) | (14.4 M) | (23.4 M) | (57.5 M) | (247.6 M) | (303.1 M) | (140.4 M) | (142.9 M) | (179.7 M) | (241.4 M) | (217.3 M) | (206.4 M) |
| NGNE | (10.4 M) | (10.4 M) | (7.7 M) | (9.4 M) | (22.4 M) | (21.3 M) | (37.6 M) | (51.1 M) | (23.5 M) | (24.4 M) | (41.6 M) | (50.5 M) | (56.5 M) | (55.6 M) | (82.6 M) | (74.3 M) | (70.6 M) |
| SLDB | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (25.6 M) | (54.9 M) | (75.7 M) | (119.3 M) | (86.5 M) | (72.3 M) | (106.5 M) | (104.3 M) | (129.7 M) | (116.8 M) | (122.6 M) |
| QSI | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.7 M) | (96.9 M) | (123.8 M) | (111.2 M) | (108.6 M) | (97.7 M) | (102.6 M) |
| LCTX | (700 K) | (18.7 M) | (25 M) | (56 M) | (50.7 M) | (65.8 M) | (59 M) | (38.9 M) | (41.8 M) | (38.9 M) | (26.4 M) | (49.2 M) | (22.5 M) | (24.7 M) | (21.5 M) | (19.3 M) | (20.3 M) |
| BNTC | (8.2 M) | (8.2 M) | (8.2 M) | (14.4 M) | (13.3 M) | (25 M) | (15.9 M) | (8.6 M) | 2 M | (8.3 M) | (13.6 M) | (17.9 M) | (19.1 M) | (22.6 M) | (41.8 M) | (37.6 M) | (35.7 M) |
| ADCT | (91.7 M) | (91.7 M) | (91.7 M) | (91.7 M) | (91.7 M) | (91.7 M) | (91.7 M) | (91.7 M) | (125.9 M) | (119.4 M) | (219.3 M) | (261.7 M) | (123.3 M) | (166 M) | (130.7 M) | (117.6 M) | (123.5 M) |
| ALMS | (113.8 M) | (113.8 M) | (113.8 M) | (113.8 M) | (113.8 M) | (113.8 M) | (113.8 M) | (113.8 M) | (113.8 M) | (113.8 M) | (113.8 M) | (113.8 M) | (113.8 M) | (158.2 M) | (300.8 M) | (270.7 M) | (284.2 M) |
| RCKT | (5.8 M) | (5.8 M) | (5.8 M) | (6.7 M) | (7.7 M) | (20.4 M) | (41.9 M) | (26.7 M) | (71.2 M) | (76.2 M) | (136 M) | (167.2 M) | (224.3 M) | (259.7 M) | (273.2 M) | (245.9 M) | (233.6 M) |
| NMRA | (95.5 M) | (95.5 M) | (95.5 M) | (95.5 M) | (95.5 M) | (95.5 M) | (95.5 M) | (95.5 M) | (95.5 M) | (95.5 M) | (95.5 M) | (237.3 M) | (135.9 M) | (188.2 M) | (263.5 M) | (237.1 M) | (249 M) |
PureTech Health PLC and related stocks such as Autolus Therapeutics, Neurogene, and Solid Biosciences LLC Operating Income description
Operating Income is the amount of profit realized from PureTech Health PLC operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of PureTech Health PLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| PureTech Health PLC | PRTC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 6 Tide Street, |
| Exchange | NASDAQ Exchange |
USD 18.08
Check out PureTech Health Performance and PureTech Health Correlation. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
PureTech Health technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.